2142 Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.45 |
| 52 Week High | HK$2.03 |
| 52 Week Low | HK$1.01 |
| Beta | 1.58 |
| 11 Month Change | 11.54% |
| 3 Month Change | 39.42% |
| 1 Year Change | -9.38% |
| 33 Year Change | -84.74% |
| 5 Year Change | n/a |
| Change since IPO | -86.84% |
Recent News & Updates
Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18
HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Recent updates
Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper
Apr 12HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business
May 30Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)
Apr 07Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results
Mar 31What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?
Mar 10Shareholder Returns
| 2142 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 9.0% | 7.0% | -0.4% |
| 1Y | -9.4% | -29.5% | 0.6% |
Return vs Industry: 2142 exceeded the Hong Kong Biotechs industry which returned -29.5% over the past year.
Return vs Market: 2142 underperformed the Hong Kong Market which returned 0.6% over the past year.
Price Volatility
| 2142 volatility | |
|---|---|
| 2142 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2142's share price has been volatile over the past 3 months.
Volatility Over Time: 2142's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 177 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7.
HBM Holdings Limited Fundamentals Summary
| 2142 fundamental statistics | |
|---|---|
| Market cap | HK$1.08b |
| Earnings (TTM) | HK$177.98m |
| Revenue (TTM) | HK$698.76m |
6.0x
P/E Ratio1.5x
P/S RatioIs 2142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2142 income statement (TTM) | |
|---|---|
| Revenue | US$89.50m |
| Cost of Revenue | US$2.03m |
| Gross Profit | US$87.47m |
| Other Expenses | US$64.67m |
| Earnings | US$22.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.031 |
| Gross Margin | 97.73% |
| Net Profit Margin | 25.47% |
| Debt/Equity Ratio | 53.8% |
How did 2142 perform over the long term?
See historical performance and comparison